Lead Sponsor

Novo Nordisk A/S

Age

All ages

Sex

ALL

Healthy Volunteers

No

•Signed informed consent by the patient or next of kin or legally acceptable representative to collect data on treatment of a given bleeding episode, surgical event or prophylactic regimen as specified in the protocol. If informed consent is provided by the next of kin or legally acceptable representative, consent must also be obtained from the patient as soon as he/she is able to do so. Informed consent should preferentially be obtained before initiation of treatment or as a minimum before entry of data into the database
•Any patient with a FVII deficiency for whom treatment of bleeding episodes, prevention related to surgery and primary/secondary prophylaxis is considered necessary by the treating physician can be enrolled
•Patients with FVII deficiency without any immediate need for treatment will be entered as stand by registered patients with capture of baseline- and demographic data only. Admission data is entered once an event occurs

Related studies

NCT02137850 · Congenital Bleeding Disorder, Haemophilia A

NCT02141074 · Congenital Bleeding Disorder, Haemophilia B

NCT01561391 · Congenital Bleeding Disorder, Haemophilia A With Inhibitors, and more

NCT03075670 · Congenital Bleeding Disorder, Haemophilia B

NCT03528551 · Congenital Bleeding Disorder, Haemophilia A

Treatment of Congenital Factor VII Deficiency